le Coutre P, Burchert A, Saussele S, Schwarzer T, et al. Favorable rates of cardiovascular events with stringent cardiovascular monitoring and a lowered dose of ponatinib as second line treatment in chronic phase chronic myeloid leukemia (CML-CP) patients failing or intolerant to first-line second generatio Acta Haematol 2025 May 5:1-13. doi: 10.1159/000545826.
PMID: 40324350